The traditional model of chemotherapy administration relied heavily on the administration of parenteral agents in the ambulatory setting, either in hospital-based centers, private physician practices, or outpatient centers. In recent years, the approval of several new oral antineoplastic agents has shifted antineoplastic therapy delivery to patients’ homes, extended care facilities, and rehabilitation centers. This shift to oral therapy allows for greater patient convenience, fewer trips to clinics, and improved patient quality of life. However, difficulty coping with side effects, patient and family safety, dosing, and cost has raised concerns of patient adherence. This new form of therapy can be both exciting and demanding.
This course explores the shift to oral antineoplastics and provides clinicians with tools for managing patients receiving oral therapies. Nurses who are caring for patients receiving oral therapy should be able to counsel patients on scheduling and side effect prevention and management and recognize potential adherence concerns.
This program is supported through an educational grant provided by Novartis. There is no non-commercial support for this program.
Certification Blueprint Topic for ILNA
OCN Blueprint Topic: Cancer treatment modalities; Symptom management; Professional Performance
AOCNP Blueprint Topic: Cancer Treatment; Side Effect & Symptom Management; Professional Practice
AOCNS Blueprint Topic: Cancer Treatment; Side Effect & Symptom Management; Professional Practice
Learn more about the ILNA Renewal Method.
